Table 1.
Clinical characteristics and anti-β2GPI/HLA-DR antibody prevalence in women with RPL and women in the control group.
| RPL n = 462 |
Control n = 488 |
p-Value | |
|---|---|---|---|
| Age (years) | 35.5 ± 4.7 | 33.6 ± 5.3 | <0.001 |
| BMI (kg/m2) | 21.5 ± 3.5 | 22.5 ± 4.4 | <0.001 |
| Gravidity (no) | 3.7 ± 1.7 | 1.9 ± 1.0 | <0.001 |
| Parity (no) | 0.5 ± 0.7 | 0.8 ± 0.8 | <0.001 |
| History of spontaneous miscarriages (no) | 2.8 ± 1.4 | 0.1 ± 0.3 | <0.001 |
| History of stillbirths at 22 GWs or later (no) | 0.05 ± 0.3 | 0.01 ± 0.09 | <0.001 |
| History of thrombosis | 4 (0.9%) | 0 (0%) | 0.06 |
| Autoimmune diseases | 34 (7.4%) | 0 (0%) | <0.001 |
| Use of immunosuppressive drugs | 9 (1.9%) | 0 (0%) | <0.01 |
| Chronic hypertension | 2 (0.4%) | 0 (0%) | 0.2 |
| Smoking habit | 41 (8.9%) | 40 (8.2%) | 0.8 |
| Anti-β2GPI/HLA-DR antibody positive | 78 (16.9%) | 27 (5.5%) | <0.001 |
Data are expressed as means ± standard deviations or numbers (percentages). Abbreviations: β2GPI, β2-glycoprotein I; HLA, human leukocyte antigen; RPL, recurrent pregnancy loss; BMI, body mass index; no, number; GWs, gestational weeks.